Regeneron Pharma posts quarterly profit on $228 mln gain


Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O reported a quarterly profit on Wednesday that rose more than four times, helped by a $228 million gain and on higher sales of its blockbuster eczema treatment Dupixent.

Net income rose to $897.3 million, or $7.61 per share, in the second quarter ended June 30, from $193.1 million, or $1.68 per share, a year earlier.

Revenue rose to $1.95 billion from $1.58 billion.

(Reporting by Dania Nadeem and Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)

((; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3463))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.